

REMARKS

Claims 1, 7-9, 19-22, 25, 28, 30, 55, 63, 64, 71, 76, 79, 80 and 93 were pending in the subject application. In the current Office Action, the claims have been subjected to a restriction requirement. By this amendment, applicants have canceled Claims 9, 19-22, 25, 28, 30, 55, 63, 64, 71, 76, 79, 80 and 93, which include claims directed to non-elected inventions, without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a future divisional or continuation application. New Claims 94-110 correspond to previously canceled claims. Support for new claims 94-110 can be found in the specification at, *inter alia*, page 10, line 3 to page 11, line 5. Therefore new Claims 94-110 do not introduce new matter. Accordingly, entry of the claim amendments is respectfully requested.

Restriction Requirement

The Examiner required restriction to one of the following four Groups of inventions under 35 U.S.C. §§121 and 372:

- I. Claims 1 and 7-9, drawn to an inhibitor of PKC α having the peptide sequence as claimed, classified in class 530, subclass 328;
- II. Claims 19-22, 25 and 28 drawn to an inhibitor comprising the peptide sequence as claimed, classified in class 530, subclass 327;
- III. Claim 30, drawn to a combinatorial library, classified in class 435, subclass 7.1;
- IV. Claim 55, drawn to a method of identifying an inhibitor of a protein kinase, classified in class 435, subclass 7.1;
- V. Claims 63, 64, 71 and 76, drawn to a method of treating a condition dependent on PKC, classified in class 514, subclass 2+; and

Applicant: David S. Lawrence
Appl'n. No.: 10/589,029
Filed: June 21, 2007
Page 9


VI. Claims 92 and 93, drawn to a method of treating a condition dependent on PKC, classified in class 514, subclass 2+.

In response to the restriction requirement, applicants hereby elect, without traverse, the invention identified by the Examiner as Group I, i.e., Claims 1, 7 and 8, drawn to an inhibitor of PKC α having the peptide sequence as claimed.

Election of Species Requirements

The Examiner required that applicants elect a single species of inhibitor if Group I is elected.

In reply, Applicant elects the inhibitor comprising



Applicants maintain that Claims 1, 7, 8, 94-98, 109 and 110 are readable on the elected species.

Applicant: David S. Lawrence
Appl'n. No.: 10/589,029
Filed: June 21, 2007
Page 10


CONCLUSIONS

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required to maintain the pendency of the subject application, authorization is hereby given to withdraw the amount of any such fee from Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: October 17, 2008
New York, New York

By 
Jeffrey C. Shieh, Reg. No. 61,862